OCGN | Ocugen
Next ER: March 27, 2020 Before Market Opens
Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.
More profiles and info about the company
This company doesn't provide a dividend.
Talk about Ocugen below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Want to know the strategies of successful swing trading? This friendly guide covers the ins and outs of this risky but profitable investing approach, explaining all the basics in plain English. You'll see how to use the two investment approaches - technical and fundamental analysis - to indentify promising securities in strongly trending markets. In addition, this guide covers how to calculate investment returns and, most important, how to manage your portfolio's risk.
Take advantage of price swings in strongly trending securities and pump up your portfolio!